Uncategorized Archives - Page 62 of 87 - PsychedelicNewsWire (PNW)

TuesdayAug 25, 2020 11:16 am

Psychedelics Decriminalization Petition Awaits Response from the Canadian Government

A petition that called for the decriminalization of psychedelics garnered about 15,000 signatures surpassing the required 500 signatures and will be read formally in the House of Commons after sessions resume on September 23. It talks about the different uses of entheogen plants and fungi as well as the substances’ therapeutic potential. After it’s been introduced, the government has 45 days to put out a response. The MP Paul Manly of the Green Party who sponsored the petition revealed bigger plans for the bill, saying that he’d continue his support while pushing for decriminalization of possession of all drugs that…

MondayAug 24, 2020 10:00 am

Oakland Activists Unveil Guidelines for Planned Psychedelic Healing Ceremonies Upon Prospective Legalization

Lawmakers in Oakland have achieved a major milestone in the use of psychedelics when they spearheaded a successful drive to decriminalize plant and fungi-based psychedelics. The move allows members of the public to consume ayahuasca and psilocybin mushrooms without fear of landing in jail. In their next push to legalize psychedelic healing ceremonies, the psychedelics activists have rolled out a myriad of safety guidelines that participants in entheogenic healing ceremonies will follow once legalization occurs. The healing ceremonies involve the use of entheogenic substances believed to have healing capabilities. So far, the practice awaits legislation to have legal backing. Decriminalize…

FridayAug 21, 2020 2:00 pm

Eleusis Sheds Light on the Asthma-Fighting Properties of Psychedelics

The medical community has always had keen interest in psychedelics, such as LSD, for their anti-inflammatory properties. However, the stigma associated with these substances, together with the prohibitive laws in force, have made the therapeutic exploitation of psychedelics a difficult undertaking. The recent interest directed towards psychedelics has allowed Eleusis Ltd., a psychedelics company, to investigate the different psychedelics in order to find out which ones have potent anti-inflammatory attributes. The researchers employed by the company looked at about 21 psychedelics which target a specific serotonin receptor (5-HT2A). When this receptor is activated, anti-inflammatory effects are observed in asthmatics. The…

ThursdayAug 20, 2020 9:00 am

Psycholytic vs. Psychedelic Therapy

With psychedelic-assisted therapy now getting airtime on major media outlets and channels like CNN and Bloomberg, it is safe to say that psychedelics have now gone mainstream. However, the media doesn’t provide as much detailed information as the public needs since the media is driven by the lure of the shareable sound bite and the sensational headline. For this reason, many members of the public may use the term psychedelic therapy when referring to psycholytic therapy, yet these concepts aren’t interchangeable. To clear this confusion, we have prepared the following analysis of these related forms of therapy. Psychedelic Therapy In…

WednesdayAug 19, 2020 3:30 pm

Johns Hopkins Researchers Invite Real World Psychedelics Users to Share Their Experiences

A team of researchers from Johns Hopkins University are calling on people who use psychedelics to enroll for their new study that is geared at understanding the real-world effects of taking psychedelic substances like shrooms (magic mushrooms). The Johns Hopkins researchers are working together with Unlimited Sciences, a Denver-based nonprofit which is funding this “real-world” study. The intention is to get insights into the factors which impact psychedelic trips and the outcomes of those trips. To this end, the researchers are asking anyone who plans, for whatever reason, to take psychedelics, to enroll. They are also open to people taking…

WednesdayAug 19, 2020 11:45 am

Cybin Corp. Ideally Positioned as Landmark Decision Regarding Psilocybin Therapy Could Spark Increased Interest, Use

Canada’s Minister of Health approves the use of psilocybin therapy in end-of-life care of four Canadians battling incurable cancer The Decision marks first legal, medical exemptions for psilocybin use in Canada since the compound became illegal in 1974 Cybin subsidiary Serenity Life Sciences focuses on advancing R&D of psilocybin-based pharmaceutical products A ground-breaking decision by Canada’s Minister of Health, the Honourable Patty Hajdu, to approve the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU) bodes well for companies such as Cybin Corp., which are operating in the psilocybin sector. An exemplary Canada-based, life-sciences company,…

TuesdayAug 18, 2020 2:00 pm

Congressman Says Psychedelics Are a Promising Treatment for PTSD

It is rare to hear anyone on Capitol Hill talking about psychedelics, but Rep. Joe Kennedy III, a Democrat from Massachusetts, has not only changed his stance from being anti-marijuana legalization lawmaker to one in favor of cannabis policy reform and he even said that certain psychedelics show a lot of promise as treatments for depression and post-traumatic stress disorder (“PTSD”). This statement by the Congressman is interesting for a number of reasons. First, Democrats in the House of Representatives heavily voted against an amendment which would have paved the way for research into a number of psychedelics, such as…

TuesdayAug 18, 2020 10:35 am

Pure Extract Technologies Inc. Focused on Becoming Dominant Extraction Company, Poised for Rapid Growth in Expanding Mushroom Market

Vast potential of mushroom medicine market is hindered by lack of pharma-grade extracts preventing brands from seizing this market opportunity Traditional extract producers limited by low-volume, non-scalable manufacturing methods Pure Extracts equipped to produce urgently needed pharma-grade psilocybin Pure Extracts, a Canadian plant-based extraction company operating in the functional medicinal mushrooms space, is in a unique position to become the dominant extraction company and a leader in the rapid development and commercialization of functional medicine products. With its substantial experience and technical competence in plant extraction creating a distinctive competitive advantage, Pure Extracts is focused on becoming a critical partner…

MondayAug 17, 2020 12:41 pm

Cybin Corp. Enters Feasibility Agreement to Develop Fast-Acting Psilocybin Film

Agreement with leading drug-delivery company outlines plans to develop fast-acting, orally dissolving film for delivery of pharmaceutical-grade psilocybin Cybin CEO notes that systemic bioavailability of film is projected to be high Cybin focused on developing fungi-derived psychedelic, medicinal products to treat mental illness, other health conditions Cybin Corp. announced that it has entered into a feasibility agreement with IntelGenx Corp., a leading drug-delivery company focused on the development and manufacturing of pharmaceutical delivery films (http://ibn.fm/TZeVy). The agreement outlines plans for the two companies to develop a fast-acting, orally dissolving film for the delivery of pharmaceutical-grade psilocybin. “We at Cybin are proud…

MondayAug 17, 2020 11:15 am

The Role of Psychedelic Products in Medicinal Treatments

Scientists are embarking on a new frontier in medicinal treatment. The successful use of controlled psychedelic products is becoming widely accepted by universities, government and research institutes and health care organizations to treat a variety of mental health issues, including anxiety and depression. In the last decade, breakthrough findings have been published about the usefulness and application of psychedelic compounds like psilocybin, more commonly referred to as magic mushrooms. Psilocybin is a naturally occurring psychedelic prodrug compound, which is produced by more than 200 species of mushrooms. After obtaining U.S. regulatory approval to research psychedelics in healthy volunteers, Johns Hopkins…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized